Ergocalciferol
Vitamin D and Analogues
Sold as VITLIPID N ADULT · VITLIPID N INFANT
- Drug class
- Vitamin D and Analogues
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 8
- FDA reports (12 mo)
- 23,014
Overview
Ergocalciferol is an active pharmaceutical ingredient in the Vitamin D and Analogues group (A11CC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 7 | April 17, 2026 |
| US United States | FDA | 1 | May 20, 2026 |
GBUnited Kingdom· MHRA
7 products
Uses
As a supplement for the prevention of vitamin deficiency states. As an aid to the maintenance of normal health and growth in infants and young children.
How to take
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.
How to take
Drug interactions
Known interactions involving Ergocalciferol. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL432170007 · revised September 27, 2024
- [2]FDA DailyMed · 0d230fd8-2ea7-4d… · revised May 20, 2026 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.